Tadalafil Mylan 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
WS/2431 
This was an application for a variation following a 
12/05/2023 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
authorisation, including the RMP - Other variation 
IA/0022 
B.II.d.2.a - Change in test procedure for the finished 
20/07/2022 
n/a 
product - Minor changes to an approved test 
procedure 
N/0021 
Minor change in labelling or package leaflet not 
15/06/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
T/0020 
Transfer of Marketing Authorisation 
12/08/2021 
15/09/2021 
SmPC, 
Labelling and 
PL 
IA/0019/G 
This was an application for a group of variations. 
04/03/2021 
15/09/2021 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IAIN/0018/G 
This was an application for a group of variations. 
17/06/2020 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0017 
B.II.b.2.c.1 - Change to importer, batch release 
11/12/2019 
17/09/2020 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0016/G 
This was an application for a group of variations. 
18/09/2019 
17/09/2020 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
R/0014 
Renewal of the marketing authorisation. 
29/05/2019 
31/07/2019 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of 
PL 
Tadalafil Mylan in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IAIN/0015/G 
This was an application for a group of variations. 
01/07/2019 
n/a 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
N/0013 
Minor change in labelling or package leaflet not 
07/03/2019 
31/07/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0012/G 
This was an application for a group of variations. 
14/01/2019 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
T/0011 
Transfer of Marketing Authorisation 
25/07/2018 
03/08/2018 
SmPC, 
Labelling and 
PL 
IB/0009 
C.I.z - Changes (Safety/Efficacy) of Human and 
08/11/2017 
12/04/2018 
SmPC 
Veterinary Medicinal Products - Other variation 
IAIN/0010/G 
This was an application for a group of variations. 
07/11/2017 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
control/testing takes place 
IB/0008/G 
This was an application for a group of variations. 
27/06/2017 
12/04/2018 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
A31/0005 
Pursuant to Article 31 of Directive 2001/83/EC, 
23/03/2017 
23/06/2017 
Please refer to the assessment report:  
several member states requested on 14 December 
2016 the opinion of the European Medicines Agency 
further to critical findings following GCP inspections 
by the Austrian and Dutch inspection authorities at 
Micro Therapeutic Research Labs Ltd, India. The 
CHMP was requested to assess the impact thereof on 
the benefit-risk balance of several products (amongst 
Tadalafil Mylan - EMEA/H/A31/1450/C/003787/0005 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
them Tadalafil Mylan) and to give its 
recommendation whether the marketing 
authorisation of this product should be maintained, 
varied, suspended, revoked or the marketing 
authorisation applications not to be granted. 
IB/0007 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
18/04/2017 
12/04/2018 
SmPC, 
life of the finished product - As packaged for sale 
(supported by real time data) 
Labelling and 
PL 
IAIN/0006 
B.II.e.5.a.1 - Change in pack size of the finished 
16/02/2017 
23/06/2017 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
IB/0004 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
12/10/2016 
23/06/2017 
SmPC, 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
Labelling and 
PL 
IG/0647 
C.I.8.a - Introduction of or changes to a summary of 
11/01/2016 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IA/0002 
B.III.1.a.2 - Submission of a new/updated or 
21/12/2015 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0001 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/11/2015 
02/12/2015 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 7/7 
 
 
 
 
 
 
 
 
 
